BAJAJ BROKING
Biocon inaugurated its first US manufacturing facility in Cranbury, New Jersey, through Biocon Generics Inc. The plant, acquired in 2023, received $30 million investment and has an annual capacity of 2 billion tablets.
Source: Biocon Press Release (NSE Exchange Fillings) | Published on Sept 11, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from Biocon (NSE Exchange filings), the company reported the opening of its first US production facility in Cranbury, New Jersey. The Oral Solid Dosage (OSD) facility which would be wholly owned by the company through its subsidiary Biocon Generics Inc., is a key step in the company’s global expansion strategy.
Biocon inaugurates first US plant in New Jersey.
Facility acquired in 2023 from Eywa Pharma Inc.
$30 million invested to expand operations.
Annual production capacity: 2 billion tablets.
Some products already commercialised from the site.
Also read: Adani Ports arm acquires Dependencia Logistics for ₹38 crore deal
In 2023, Biocon purchased the OSD plant from Eywa Pharma Inc. and has since spent around USD 30 million to upgrade and refurbish it. The site is able to produce up to 2 billion tablets per year. This is a substantial addition to Biocon's portfolio. The company has already launched several products from the facility, and will likely add others in the near future.
The Cranbury site is a very solid addition to the Biocon global network. For you as someone tracking growth in pharmaceuticals, this acquisition exemplifies how businesses broaden their footprint by acquiring products in alternate geographical markets and diversify their manufacturing bases. The facility will strengthen your supply chain and improve the speed with which therapies will be made available across the US market. Noting such expansions will give your review of company performance relative to changes in the Biocon share price better context.
Particulars | Details |
Location | Cranbury, New Jersey, US |
Acquisition Year | 2023 (from Eywa Pharma Inc.) |
Investment | USD 30 million |
Annual Capacity | 2 billion tablets |
Operating Subsidiary | Biocon Generics Inc. |
Biocon's share price on the BSE closed at ₹345.20 on September 11, 2025 at 15:30 PM IST and was up 0.42% from the previous close. For you as an investor, continuing to focus on the company’s financial results along with operational growth, such as this facility, will provide a much better perspective of its performance trajectory. The market reaction to these company strategies is usually a combination of the expansion news and the overall quarterly performance.
If you follow healthcare stocks closely, Biocon's advancement into manufacturing in the US is a great illustration of how businesses go global and secure significant markets. For you, this represents having a sounder frame of reference when reviewing the Biocon share price metrics, and grasping any difference in long-term supply potential and worldwide access from infrastructure investments.
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading